17th Oct 2013 10:17
LONDON (Alliance News) - Biotechnology company Avacta Group PLC said Thursday that it had signed a licensing agreement with Blueberry Therapeutics Limited to use its Affirmer technology to develop new therapies to treat drug resistant bacterial infections.
Under this deal Avacta will provide Affirmers to Blueberry for their drug development programmes, and has already supplied the first lead Affirmer.
Affirmers are engineered alternatives to antibodies.
Shares in Avacta were trading up 4.5% at 0.914 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group